Dilemma of Antiepileptic Drugs Withdrawal in Symptomatic Epilepsy by Dubravka Šepić Grahovac et al.
Coll. Antropol. 35 (2011) 4: 1291–1294
Case report
Dilemma of Antiepileptic Drugs Withdrawal
in Symptomatic Epilepsy
Dubravka [epi} Grahovac1, Goran Bajek1, Dinko Vitezi}1, Lidija Tu{kan Mohar1,
Antonija Ru`i} Bar{i}2, Tanja Grahovac1 and Snje`ana Bajek1
1 University of Rijeka, School of Medicine, Rijeka, Croatia
2 University of Rijeka, Rijeka University Hospital Center, Department of Radiology, Rijeka, Croatia
A B S T R A C T
A successful treatment of epilepsy depends on numerous factors such as etiology, genetics and environmental impact.
An exact diagnosis, treatment and an adequate selection of antiepileptic drugs (AED) are important from the very begin-
ning. The patient with symptomatic epilepsy caused by the brain tumor (low-grade astrocytoma in the left parietal lobe,
surgically removed 17 years after the first manifestation of illness) is presented in this study. He has been seizure free for
6 years. The represented case study deals with the risk-benefit analysis of the discontinuation of the prescribed anti-
epileptic treatment that has lasted for 23 years.
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Introduction
The aim of this report is to discuss the withdrawal of
AEDs in a patient with a good clinical outcome and the
well-known etiological factor of seizures, i.e., low-grade
astrocytoma. Symptomatic epilepsy is caused by variable
pathology. Between 3 and 5% of epileptic seizures can be
attributed to the central nervous system (CNS) neo-
plasm1,2. Most AEDs suppress the seizure occurrence but
do not prevent the epileptogenesis. Etiology is one of the
most important determinants for the outcome of the de-
cision to discontinue AEDs3. Many physicians meet the
dilemma of AEDs withdrawal in patients but their expe-
riences have rarely been reported in literature. Although
the prevalency of epilepsy is very high among world pop-
ulation (one percent)4, the definitive guidelines for the
discontinuation of AEDs still do not exist.
Case Report
We present a 58-year-old right-handed male clerk,
who had a brief loss of consciousness without seizures at
the age of 35, while he was playing football. Five months
later, he had a partial motor seizure in his right arm with
the secondary generalization, without aura. His wife re-
ported his postictal changes of mood during the half an
hour. A sleepless night, mild alcohol consumption and
physical fatigue preceded the seizure. In the family his-
tory, there were no members with epilepsy. Disrrhythmia
was recorded on electroencephalogram (EEG) and the
treatment with AED (methyphenobarbital 200 mg per
os) was started. The performed brain computed tomogra-
phy (CT) showed the extensive damage of cortical and
subcortical tissues in the area of left parietal lobe, which
was interpreted as gliosis (Figure 1).
The patient refused the proposed brain biopsy. The
control neuroimaging techniques (CT/MRI) were per-
formed once a year during the next eight years. The ther-
apy with methyphenobarbital 200 mg and carbamazepin
400 mg, twice daily per os, was continued regularly and
he became seizure free. Between the age 43 and 50, sei-
zures of the same origin started to reappear once or twice
a year, in spite of his taking the therapy regularly. The
magnetic resonance scan (MRI) of the brain repeatedly
showed the wide damage of the left frontal and parietal
lobe. At the age of 51, during an enterovirosis accompa-
nied by high fever, he had a series of focal seizures with
secondary generalization. The MRI confirmed the previ-
ous findings that had shown additional expansive cystic
formation, with no pressure on the surrounding tissue at
the same localization (Figure 2). The stereotactic biopsy
verified the astrocytoma II / III grade in the area of de-
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scribed lesions. A year later, at the age of 52, the tumor
was neurosurgically removed. In the early postoperative
stage, during the first week, an isolated partial seizure
with secondary generalization occurred. The neurologi-
cal examination showed a moderate right side hemy-
paresis and a sensomotor paraphasis. A massive AED
politherapy was prescribed: phenobarbiton 500 mg, car-
bamazepin 1200 mg, phenitoin 300 mg, lamotrigin 300
mg orally and 30 brachytherapy treatments. The right
side hemyparesis of central type and sensomotor para-
phasis withdrew greatly through neurorehabilitation pro-
cedures. Psychomotor slowness and excessive sedation as
the side effects of AEDs were corrected during the follow-
ing 3 months. 5 years after the surgery, a control MRI of
the brain showed a post-operational gliosis without the
residual tumor (Figure 3). The MRI spectroscopy of the
selected areas of the left precentral area detected the cor-
rect relationship between the basic metabolites cholin
and sodium–acetylaspartat. Presently, the patient is do-
ing well, despite the presence of discrete right central
hemyparesis. His mental functions and professional abil-
ities have been preserved. He has continued with AEDs:
lamotrigin 100 mg and phenobarbital 50 mg. He has had
no seizures in last 6 years. Routine laboratory tests are
within the normal range.
Discussion
The late onset epilepsy traditionally leads us to con-
sider the presence of brain tumors. About one third of
brain tumors have seizures as a presenting symptom1,
but only in 10 to 15%, epileptic seizures are the first
manifestation of the intracranial expansive process. Sei-
zures that follow the development of tumors do not have
the same significance as those that occur at the begin-
ning of the process. That corresponds to the classic defi-
nition of the late onset epilepsy, which could be the mani-
festation and the only symptom of the intracranial ex-
pansive process that can evolve or remain isolated during
months, even years5.
The use of neuroimaging techniques (brain CT, con-
ventional and unconventional MRI scans), which en-
abled an early diagnosis, today significantly modify that
term. The risk is dependent on the age; because almost
three quarters of epileptic seizures, which are caused by
CNS tumors, appear between the age of 20 and 50. That
usually includes supratentorially located tumors. The
studies have shown that most epileptogenic tumors are
in greatest part benign, or have a low evolutive potential,
such as oligodendroglioma, astrocytoma and meningeoma1.
Our patient is an example for these statements. He
lived with an astrocytoma (II/III grade) for 17 years,
which is very well described in clinical neurological pra-
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Fig. 1. Brain CT in 1988 showed extensive damage in the left pa-
rietal lobe.
Fig. 2. MRI in 2002 showed the expansive cystic formation at the
same localization.
Fig. 3. MRI in 2008 (5 years after the surgery) showed gliosis
without the residual tumor.
ctice6. Malignant gliomas and metastases are signifi-
cantly less epileptogenic. Arachnoidal cysts generally do
not have any connection with the epileptic focus and sur-
gical treatment is always questionable7. A clinical epilep-
tic expression primarily depends on the localization and
the size of the tumor. Partial epileptic seizures, especially
somato-motoric ones are predominant over the second-
ary generalized seizures4. The electroencephalographic
semiology may be absent, and then be falsely comforting.
The most common finding is a focally changed EEG that
shows the localization of the process.
Neuroradiological findings are those that confirm the
diagnosis. Mostly primary partial seizures are rarely pre-
sented as secondary generalized seizures, they aggravate
the clinical picture and can cause a possible decom-
pensation of the present tumor, especially in low-grade
astrocytoma. A long-term AED treatment is indicated in
the preoperational and in the post-operational stage, as
in the case of symptomatic epilepsy. Such prophylactic
treatment is not indicated if efficiency is not proved and
with regard to the numerous side-effects, especially cog-
nitive, as well as the potential interactions between
AEDs and other drugs, such as chemotherapeutics8. Lar-
ge retrospective studies have reported that patients with
brain tumors are more likely to be controlled with AEDs
than those with malformations of cortical development,
hyppocampal sclerosis or post-traumatic epilepsy9.
Causes of seizures are the most important factor for
the outcome of the treatment10. A possible and/or success-
ful removal of the main cause of epilepsy (brain tumor in
our case) can have an influence on its favorable evolution11.
On the other hand, approximately 60 to 70% of pa-
tients accomplish a good control of seizures, even their
disappearance, by the regular taking of AEDs, during a
long period of treatment12,13. If we exclude an epileptical
seizure that followed the day after surgery, our patient’s
epilepsy became well controlled by taking AEDs, and the
patient has been seizure free for 6 years.
The issue of the withdrawal of AEDs in this case is
very plausible. A Cochrane review concluded that the op-
timal period for the discontinuation of AEDs in adults re-
mains uncertain and unspecified14. However, according
to 2nd UCB Global Epilepsy Summit most patients with
epilepsy should have an attempted treatment withdra-
wal if they have been seizure free for 2–3 years15. The pe-
riod of discontinuation varies. The recent Cochrane re-
view did not come to any reliable conclusion on the
optimal taper rate16. The results of the MRC study indi-
cate that a shorter period without epileptic seizures be-
fore the discontinuation of AEDs significantly increases
the risk for recurrences17. A gradual withdrawal, choos-
ing a suitable period in a patient’s life and creating a pro-
tected environment, are conditions for starting the dis-
continuation15. Some studies have shown that the dis-
continuation needs to be performed slowly, because if a
relapse occurs during the taper, the seizure may be less
severe than after the full withdrawal18. According to the
recent data, the treatment should be discontinued gradu-
ally over a period of 6 months to 1 year15. Subclinical
(subtoxic) AEDs’ side effects, absent in our patient, may
also be a reason for the withdrawal.
An absolute answer for AED discontinuation does not
exist19,20. The benefits and risks associated with the AED
withdrawal need to be balanced18. Benefits, besides sav-
ings, are the disappearance of secondary mental side ef-
fects, the elimination of teratogenesis (in pregnant wo-
men with epilepsy)18, subjective effects in the patient and
the stigmatization of the illness. Some risks for recur-
rences are: a patient’s disrespect for the way of living
with the epilepsy, ignoring the advices of physicians; a
desire for full inclusion in the social and professional life
and a desire for keeping driving ability20,21 and for prac-
ticing sports. A sudden appearance of the status epi-
lepticus is rare if the withdrawal is performed gradually.
Some authors state that over 40% of patients who termi-
nated the treatment with AEDs have relapses, while only
2% of those who continue with the therapy also continue
with seizures22. Before the interruption of the treatment,
it is necessary to obtain the informed consent, with the
obligatory warning about possible relapses but also bene-
fits of such a decision23. In our case, preferable factors for
the AED withdrawal are: a normal electroencephalo-
gram23 and the surgical removal of the tumor that caused
the epileptical focus. Doubts about this decision result
from the inability to prove completely the effectiveness
of a surgical treatment. Several years after the absence
of epileptic seizures, we cannot know if the absence is re-
ally a consequence of successful treatment or if the natu-
ral development of the disease has been favorable. The
ictal and interictal EEG registration23 is not an absolute
criterion, but can be very useful. A discontinuation of
AEDs must be presented to the patient as an attempt,
and the process must be performed gradually. Our expe-
rience has shown that it is necessary to gradually initiate
the monotherapy, and then slowly reduce the dosage
(25% every three months). Some AEDs (e.g. barbitu-
rates) can produce a complex syndrome of abstinence. Af-
ter ten or more years of the treatment with such AEDs,
some authors prefer to continue with minimal doses of
barbiturates, rather than have a withdrawal.
Conclusion
The decision to withdraw AEDs is not simple, and
cannot be infinitely delayed. In any case, the discontinu-
ation of AEDs must be strictly individualized3,20 and
based on several important factors that include the his-
tory of the disease (the age at the onset, the type and se-
verity of seizures, particular neurological findings, ab-
sence of epilepsy and mental illness/disorder in family
history)21, involvement in socio-professional life20, as well
as the decision and willingness of the patient.
The experiences of AED withdrawal are still limited,
especially in patients with symptomatic epilepsy (brain
tumor in our case). There is a need for conducting prospe-
ctive studies where the withdrawal of AEDs can be well
monitored and then to cumulate the knowledge for the
development of guidelines for the discontinuation of AEDs.
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DILEMA O UKIDANJU ANTIEPILEPTI^KIH LIJEKOVA U SIMPTOMATSKOJ EPILEPSIJI
S A @ E T A K
Uspje{no lije~enje epilepsije ovisi o brojnim ~imbenicima kao {to su etiologija, genetika i utjecaj okoli{a. To~na dijag-
noza, lije~enje i odgovaraju}i odabir antiepilepti~kih lijekova presudni su od samog po~etka za prestanak napadaja i
postizanje {to bolje kvalitete `ivota bolesnika sa epilepsijom. Prikazujemo bolesnika sa simptomatskom epilepsijom
uzrokovanom tumorom mozga (astrocitom niskog stupnja) u lijevom tjemenom re`nju, kirur{ki odstranjenog 17 godina
nakon pojave prvog epilepti~kog napadaja kao inicijalnog simptoma bolesti. Bolesnik je bez napadaja 6 godina nakon
operacije, uz diskretni neurolo{ki ispad i na minimalnoj dozi antiepileptika. Ovaj prikaz slu~aja predstavlja analizu
rizika i dobrobiti ukidanja antiepileptika nakon 23 godine.
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